315 related articles for article (PubMed ID: 15483085)
1. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
Escudero EL; Boerrigter PJ; Bennink HJ; Epifanio R; Horcajadas JA; Olivennes F; Pellicer A; Simón C
J Clin Endocrinol Metab; 2005 Apr; 90(4):2081-8. PubMed ID: 15483085
[TBL] [Abstract][Full Text] [Related]
2. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
[TBL] [Abstract][Full Text] [Related]
3. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
4. Administration of human luteinizing hormone (hLH) to macaques after follicular development: further titration of LH surge requirements for ovulatory changes in primate follicles.
Zelinski-Wooten MB; Hutchison JS; Chandrasekher YA; Wolf DP; Stouffer RL
J Clin Endocrinol Metab; 1992 Aug; 75(2):502-7. PubMed ID: 1639951
[TBL] [Abstract][Full Text] [Related]
5. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
European Recombinant LH Study Group
J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
[TBL] [Abstract][Full Text] [Related]
6. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
[TBL] [Abstract][Full Text] [Related]
7. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
Kuang Y; Chen Q; Fu Y; Wang Y; Hong Q; Lyu Q; Ai A; Shoham Z
Fertil Steril; 2015 Jul; 104(1):62-70.e3. PubMed ID: 25956370
[TBL] [Abstract][Full Text] [Related]
8. Relationship between circulating human chorionic gonadotropin levels and premature luteinization in cycles of controlled ovarian hyperstimulation.
Copperman AB; Horowitz GM; Kaplan P; Scott RT; Navot D; Hofmann GE
Fertil Steril; 1995 Jun; 63(6):1267-71. PubMed ID: 7750599
[TBL] [Abstract][Full Text] [Related]
9. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
[TBL] [Abstract][Full Text] [Related]
10. Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment.
Messinis IE; Loutradis D; Domali E; Kotsovassilis CP; Papastergiopoulou L; Kallitsaris A; Drakakis P; Dafopoulos K; Milingos S
Hum Reprod; 2005 Nov; 20(11):3192-7. PubMed ID: 16037104
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization.
Thuesen LL; Loft A; Egeberg AN; Smitz J; Petersen JH; Andersen AN
Hum Reprod; 2012 Oct; 27(10):3074-84. PubMed ID: 22791754
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
13. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone.
Ou YC; Lan KC; Chang SY; Kung FT; Huang FJ
Taiwan J Obstet Gynecol; 2008 Jun; 47(2):168-74. PubMed ID: 18603501
[TBL] [Abstract][Full Text] [Related]
14. Initiation of periovulatory events in primate follicles using recombinant and native human luteinizing hormone to mimic the midcycle gonadotropin surge.
Chandrasekher YA; Hutchison JS; Zelinski-Wooten MB; Hess DL; Wolf DP; Stouffer RL
J Clin Endocrinol Metab; 1994 Jul; 79(1):298-306. PubMed ID: 8027245
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome.
Filicori M; Cognigni GE; Taraborrelli S; Spettoli D; Ciampaglia W; de Fatis CT; Pocognoli P
J Clin Endocrinol Metab; 1999 Aug; 84(8):2659-63. PubMed ID: 10443656
[TBL] [Abstract][Full Text] [Related]
16. Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression.
Bermejo A; Cerrillo M; Ruiz-Alonso M; Blesa D; Simón C; Pellicer A; Garcia-Velasco JA
Fertil Steril; 2014 Jan; 101(1):138-146.e3. PubMed ID: 24182413
[TBL] [Abstract][Full Text] [Related]
17. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist.
Younis JS; Matilsky M; Radin O; Ben-Ami M
Fertil Steril; 2001 Aug; 76(2):294-9. PubMed ID: 11476775
[TBL] [Abstract][Full Text] [Related]
18. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
19. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.
Saadat P; Boostanfar R; Slater CC; Tourgeman DE; Stanczyk FZ; Paulson RJ
Fertil Steril; 2004 Jul; 82(1):167-71. PubMed ID: 15237007
[TBL] [Abstract][Full Text] [Related]
20. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
